We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...

Merck, known for its prescription medicines, vaccines, and biologic therapies, has been a dominant force in oncology treatment, primarily due to the success of Keytruda. However, recent ...

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck, known for its prescription medicines, vaccines, and biologic therapies, has been a dominant force in oncology treatment, primarily due to the success of Keytruda. However, recent developments ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...